Published in Am J Manag Care on September 01, 2004
The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res (2015) 1.07
Prevention of venous thromboembolism in medical patients and outpatients. Nat Rev Cardiol (2009) 0.82
Primary prevention of venous thromboembolism in elderly medical patients. Clin Interv Aging (2008) 0.78
Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review. Crit Care (2012) 0.77
The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients. Clinicoecon Outcomes Res (2012) 0.75
Venous thromboembolism prophylaxis: Solutions are in our hands. Ann Thorac Med (2011) 0.75
Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care (2005) 0.75
Impact of thromboprophylaxis across the US acute care setting. PLoS One (2015) 0.75
Prevention of venous thromboembolism in the critically ill patient. J Intensive Care Soc (2015) 0.75
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med (2005) 7.90
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation (2011) 5.16
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20
Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol (2003) 4.10
Modifying dyspepsia management in primary care: a cluster randomised controlled trial of educational outreach compared with passive guideline dissemination. Br J Gen Pract (2003) 3.88
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol (2003) 3.80
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology (2003) 3.59
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Implementation of self management support for long term conditions in routine primary care settings: cluster randomised controlled trial. BMJ (2013) 3.49
Chronic thromboembolic pulmonary hypertension. N Engl J Med (2011) 3.37
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health (2011) 2.88
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg (2005) 2.53
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
Effect of computerized clinical decision support on the use and yield of CT pulmonary angiography in the emergency department. Radiology (2011) 2.47
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making (2007) 2.46
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Physical inactivity and idiopathic pulmonary embolism in women: prospective study. BMJ (2011) 2.34
Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med (2011) 2.32
Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med (2006) 2.28
Massive pulmonary embolism. Circulation (2006) 2.27
ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome. Mol Cell (2006) 2.26
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
The accuracy of the enzyme-linked immunosorbent assay D-dimer test in the diagnosis of pulmonary embolism: a meta-analysis. Ann Emerg Med (2002) 2.25
Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism. Circulation (2004) 2.21
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med (2009) 2.13
The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med (2004) 2.11
Upper-extremity deep vein thrombosis. Circulation (2002) 2.09
Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation (2004) 2.05
State-space modelling reveals proximate causes of harbour seal population declines. Oecologia (2013) 2.02
Consider all the evidence. Aust Nurs J (2011) 2.01
The global cost of nonoptimal blood pressure. J Hypertens (2009) 2.00
Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation (2004) 1.97
Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making (2002) 1.94
Differential roles of the COOH termini of AAA subunits of PA700 (19 S regulator) in asymmetric assembly and activation of the 26 S proteasome. J Biol Chem (2008) 1.93
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Clinical validity of a negative computed tomography scan in patients with suspected pulmonary embolism: a systematic review. JAMA (2005) 1.82
Systematic review of knowledge translation strategies in the allied health professions. Implement Sci (2012) 1.81
Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making (2012) 1.81
Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation (2005) 1.80
Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making (2002) 1.78
The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol (2008) 1.77
Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med (2005) 1.76
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health (2012) 1.76
Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation (2007) 1.75
Normal D-dimer levels in emergency department patients suspected of acute pulmonary embolism. J Am Coll Cardiol (2002) 1.75
Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis (2007) 1.70
Legislating against use of cost-effectiveness information. N Engl J Med (2010) 1.68
Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation (2003) 1.68
Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation (2009) 1.66
The cost effectiveness of gonorrhea screening in urban emergency departments. Sex Transm Dis (2005) 1.64
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med (2005) 1.64
Surgical pulmonary embolectomy: the resurrection of an almost discarded operation. Tex Heart Inst J (2013) 1.63
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
Percutaneous mechanical thrombectomy for acute pulmonary embolism: a double-edged sword. Chest (2007) 1.60
Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr (2010) 1.57
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis (2007) 1.57
Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med (2005) 1.56
Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am J Gastroenterol (2002) 1.55
International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle. Arch Intern Med (2004) 1.55
Assessing the prognosis of acute pulmonary embolism: tricks of the trade. Chest (2008) 1.54
Medication use evaluation: pharmacist rubric for performance improvement. Pharmacotherapy (2014) 1.52
Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost (2011) 1.52
Maternal diabetes and renal agenesis/dysgenesis. Birth Defects Res A Clin Mol Teratol (2010) 1.49
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS (2015) 1.49
Developmentally restricted genetic determinants of human arsenic metabolism: association between urinary methylated arsenic and CYT19 polymorphisms in children. Environ Health Perspect (2005) 1.49